MIPS Value Pathways

In recent years, the Centers for Medicare & Medicaid Services (CMS) proposed a “MIPS Value Pathways” or “MVP” policy to ease the burden placed in individuals and groups participating in the Merit-based Incentive Payment System (MIPS) under the Quality Payment Program (QPP). According to CMS, the MVP framework  “aims to align and connect measures and activities across the quality, cost, and improvement activities performance categories of MIPS for different specialties or conditions.”

Participation in MIPS via the MVP reporting option will be available in 2023. 

ASA has supported several CMS MVP policy proposals, including:

  • Establishing MVPs for patient conditions and episodes of care.
  • Encouraging shared accountability MVPs where anesthesiology measures and improvement activities are linked to surgical, primary care, and other specialist measures as well as measures that assess patient outcomes and patient-reported outcomes.  
  • Using MVPs to reduce barriers to Alternative Payment Model participation by individuals and groups.
  • Ensuring that anesthesiologists and other non-patient-facing physicians and clinicians maintain their promoting interoperability exemption. 

For Performance Year 2023, CMS approved the "Patient Safety and Support of Positive Experiences with Anesthesia MVP." Those groups choosing to report the MVP in 2023 will only need to report four quality measures, 1 high-weighted or 2 medium weighted improvement activities, and promoting interoperability measures (optional depending on your special status designation). CMS will calculate the Medicare Spending Per Beneficiary (MSPB) Clinician measure for the Cost Performance Category.

Eligible clinicians and their groups will need to choose measures from this designated list:

  • Q404: Anesthesiology Smoking Abstinence
  • Q424: Perioperative Temperature Management
  • Q430: Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy
  • Q463: Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics)
  • Q477: Multimodal Pain Management
  • AQI48: Patient-Reported Experience with Anesthesia
  • AQI69: Intraoperative Antibiotic Redosing.

Eligible clinicians and their groups also have a set of eleven (11) improvement activities to choose. 

In 2022, CMS will release additional information to walk individuals and groups through MVP reporting. ASA does not expect that scoring of an MVP will be significantly different than current MIPS scoring regulations. Those choosing to report MVPs will be able to report their data through AQI NACOR's Qualified Registry or Qualified Clinical Data Registry (QCDR) options.

For more information, please contact ASA Department of Quality and Regulatory Affairs at qra@asahq.org